Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868290 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
A Phase 2 study of ANCA-Associated Vasculitis (AAV), sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 20
- Study locations
NCT06868290 is a Phase 2 study of ANCA-Associated Vasculitis (AAV) that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 126 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT06868290, a Phase 2 study of ANCA-Associated Vasculitis (AAV), is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Conditions Studied
Interventions
- OTHER Active Comparator
- BIOLOGICAL Rapcabtagene autoleucel
- DRUG Glucocorticoids
Study Locations (20)
Other
- Novartis Investigative Site - São Paulo
- Novartis Investigative Site - Haifa
- Novartis Investigative Site - Ramat Gan
São Paulo
- Novartis Investigative Site - Barretos
- Novartis Investigative Site - São Paulo
Colorado
- University Of Colorado - Aurora
Florida
- Mayo Clinic Jacksonville - Jacksonville
Illinois
- Northwestern University - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic Rochester - Rochester
Oregon
- Oregon Health Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2030-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06868290
The ClinicalTrials.gov registry entry for NCT06868290 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ANCA-Associated Vasculitis (AAV) appearing as the primary indexed condition, and to 3 interventions - of which Active Comparator is the first listed.
NCT06868290 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Other, São Paulo, Colorado.
Frequently Asked Questions
What is clinical trial NCT06868290 about?
NCT06868290 is a clinical study titled "Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA". The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
What is the current status of trial NCT06868290?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2025-03-13. Estimated completion is 2030-05-24.
What conditions does trial NCT06868290 study?
This clinical trial studies the following conditions: ANCA-Associated Vasculitis (AAV).
What interventions are being tested in trial NCT06868290?
The interventions under investigation include: Active Comparator (OTHER), Rapcabtagene autoleucel (BIOLOGICAL), Glucocorticoids (DRUG).
Who is sponsoring clinical trial NCT06868290?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868290 being conducted?
This trial has 20 study locations across Colorado, Florida, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ANCA-Associated Vasculitis (AAV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.